How should dapagliflozin (Firxiga) be initiated and managed in patients with chronic heart failure with reduced ejection fraction, including dosing, renal function requirements, contraindications, monitoring, and patient counseling?

Dapagliflozin (Forxiga) in Chronic Heart Failure with Reduced Ejection Fraction

Initiate dapagliflozin 10 mg once daily in all patients with HFrEF (LVEF ≤40%), regardless of diabetes status, as foundational therapy alongside ACE inhibitors/ARNi, beta-blockers, and MRAs. 1

Dosing

• Standard dose: 10 mg orally once daily 2
• No titration required—start at target dose
• Take at any time of day, with or without food
• For glycemic control in diabetes: may start at 5 mg and increase to 10 mg if needed, but for heart failure indication, use 10 mg directly 2

Renal Function Requirements

Initiation Thresholds

• Can initiate if eGFR ≥25 mL/min/1.73 m² 2, 3
• The DAPA-HF trial excluded patients with eGFR <30 mL/min/1.73 m², but EMPEROR-Reduced included patients down to eGFR 20 mL/min/1.73 m² 1
• Do NOT discontinue if eGFR falls below 25 mL/min/1.73 m² after initiation—continue treatment as benefits persist 2, 4

Monitoring During Treatment

• Check eGFR before initiation 2
• Expect a transient dip in eGFR within first 2 weeks (hemodynamic effect, not tubular injury) 5, 6
• This initial decline is reversible and does not require discontinuation 3
• Long-term: dapagliflozin slows eGFR decline (-1.09 vs -2.85 mL/min/1.73 m²/year with placebo) 6

Critical caveat: Patients who experience eGFR deterioration to <25 mL/min/1.73 m² still benefit from continuation (HR 0.53 for primary outcomes) with no excess safety signals 4

Contraindications

Absolute

• Type 1 diabetes 1
• Dialysis or end-stage renal disease 2
• Severe hypersensitivity to dapagliflozin 7

Relative (Use Caution)

• Volume depletion—correct before initiating 2
• Hypotension risk—particularly in elderly ≥65 years 2

Pre-Initiation Assessment

1. Volume status: Assess for dehydration, hypotension (SBP <95 mmHg suggests caution)
2. Renal function: Measure eGFR and serum creatinine
3. Electrolytes: Check potassium (especially if on MRA or ACE-I/ARB)
4. Current diuretic dose: Document baseline loop diuretic requirements 8

Do NOT delay initiation waiting for "optimal" doses of other GDMT—start early in disease course 1

Monitoring Schedule

First 2 Weeks

• Blood pressure (watch for orthostatic hypotension)
• Volume status (signs of dehydration)
• Renal function (expect 3-5 mL/min/1.73 m² dip—this is normal) 5

Ongoing

• Renal function and electrolytes at 1-2 months, then every 3-6 months 3
• Genital hygiene assessment (most common adverse effect)
• Ketone monitoring if patient becomes acutely ill (sick day protocol)

Drug Interactions and Adjustments

Diuretics

• Do NOT routinely reduce loop diuretic dose when starting dapagliflozin 8
• In DAPA-HF, diuretic doses remained stable in most patients
• Efficacy consistent across all diuretic doses (none, <40 mg, 40 mg, >40 mg furosemide equivalent) 8
• Consider reducing diuretics only if symptomatic hypotension or volume depletion occurs

Other GDMT

• Continue ACE-I/ARB/ARNi, beta-blockers, and MRAs at current doses 1
• No dose adjustments needed for background HF therapies
• Dapagliflozin works synergistically—benefits seen even with sacubitril-valsartan (used in 11-19% of trial patients) 1

Sick Day Management

Withhold dapagliflozin during acute illness with:

• Severe dehydration or inability to maintain oral intake
• Acute kidney injury
• Major surgery or prolonged fasting (hold ≥3 days before procedure) 2
• Severe infection or sepsis

Resume when clinically stable and oral intake restored 3

Patient Counseling

Expected Benefits

• Reduced risk of HF hospitalization (30% reduction) 1
• Reduced cardiovascular death (18% reduction) 1
• Symptom improvement within 30 days 1
• Benefits regardless of diabetes status 1

Common Side Effects

• Genital mycotic infections (10-15% in women, lower in men): Emphasize genital hygiene; treat with topical antifungals without stopping drug 1
• Increased urination (osmotic diuresis—expected mechanism)
• Mild weight loss (1-2 kg from fluid loss)

Warning Signs

• Severe dizziness or lightheadedness (hypotension)
• Signs of dehydration (dry mouth, decreased urine output)
• Genital itching/discharge (treatable, rarely requires discontinuation)
• Diabetic ketoacidosis (rare but serious—educate on symptoms: nausea, vomiting, abdominal pain, confusion)

Practical Instructions

• Maintain adequate hydration
• Practice good genital hygiene
• Continue medication even if feeling better
• Stop during acute illness and contact physician

Special Populations

Elderly (≥65 years)

• Higher risk of hypotension 2
• Same efficacy and safety profile 2
• No dose adjustment needed
• Monitor volume status more closely

Chronic Kidney Disease

• Safe and effective down to eGFR 25 mL/min/1.73 m² 3, 1
• Greater absolute benefit in patients with baseline eGFR <60 mL/min/1.73 m² 6
• Continue even if eGFR declines below initiation threshold 4

Severe Heart Failure (NYHA III-IV)

• Equally effective and safe 9
• No excess adverse events
• Consider earlier initiation given higher baseline risk

Key Clinical Pearls

• Start dapagliflozin early—don't wait for optimization of other GDMT 1
• The initial eGFR dip is expected and beneficial (hemodynamic, not nephrotoxic) 5
• Persistence is excellent (95-96% at 6-12 months in real-world data) 10
• Benefits are consistent across all baseline characteristics: diabetes status, diuretic dose, renal function, age, sex 1, 6, 8
• Genital infections are manageable—treat without discontinuing drug 1